SujanaMovvaMD

Oncology • New York, NY

Hematologic Oncology, Melanoma, Sarcoma

Fox Chase Cancer Center

Join to view full profile

Dr. Movva is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Movva's full profile

Already have an account?

Office
160 East 53rd Street
New York, NY 10022

Education & Training

University of Western OntarioClass of 2003
McLaren Health Care/Flint/MSUResidency, Internal Medicine

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2018 - 2026
CT State Medical License 2023 - 2025
NJ State Medical License 2018 - 2025
NC State Medical License 2020 - 2022
PA State Medical License 2012 - 2018
GA State Medical License 2010 - 2013
NM State Medical License 2007 - 2010
MI State Medical License 2004 - 2007
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Start of enrollment: 2014 Mar 21
Completed
Phase 3
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma Start of enrollment: 2016 Mar 01
Completed
Phase 1, Phase 2
Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas Start of enrollment: 2017 Feb 21
Terminated
Phase 2
Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) Start of enrollment: 2017 Aug 08
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

22 citations
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor
Evan Rosenbaum, Ciara Marie Kelly, Sandra P. D'Angelo, Mark A. Dickson, Mrinal M. Gounder
The Oncologist. 2019-10-01
805 citations
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein Abdul-Hassan Tawbi, Melissa Amber Burgess, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze
The Lancet. Oncology. 2017-11-01
93 citations
Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets
Sujana Movva, Wenhsiang Wen, Wangjuh Chen, Sherri Z. Millis, Zoran Gatalica
Oncotarget. 2015-03-28

Press Mentions

Overall Survival Benefit for Patients with Stage III Soft Tissue SarcomasMay 30th, 2014